• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    GeoVax Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    7/2/25 4:22:55 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GOVX alert in real time by email
    govx20250702_8k.htm
    false 0000832489 0000832489 2025-07-01 2025-07-01 0000832489 govx:CommonStockParValue0001PerShareCustomMember 2025-07-01 2025-07-01 0000832489 govx:WarrantsToPurchaseCommonStockCustomMember 2025-07-01 2025-07-01
     
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     

     
    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934
     
    Date of report (Date of earliest event reported): July 1, 2025
     

     
    GEOVAX LABS, INC.
    (Exact name of registrant as specified in its charter)
     
    Delaware
    001-39563
    87-0455038
    (State or other jurisdiction of
    incorporation or organization)
    (Commission File No.)
    (IRS Employee Identification No.)
     
    1900 Lake Park Drive, Suite 380
    Smyrna, Georgia 30080
    (Address of principal executive offices) (Zip code)
     
    (678) 384-7220
    (Registrant’s telephone number, including area code)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions.
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13(e)-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
    Trading
    Symbol(s)
    Name of each exchange on which registered
    Common Stock, par value $0.001 per share
    GOVX
    The Nasdaq Capital Market
    Warrants to Purchase Common Stock
    GOVXW
    The Nasdaq Capital Market
     
    Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial reporting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     

     
     
    Item 1.01
    Entry into a Material Definitive Agreement.
     
    On July 1, 2025, GeoVax Labs, Inc. (the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with the purchasers party thereto, pursuant to which the Company agreed to issue and sell, in a public offering (the “Offering”), an aggregate of 9,235,000 common units (the “Common Units”), consisting of (A) 9,235,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and (B) common warrants (the “Common Warrants”) to purchase 18,470,000 shares of Common Stock (the “Common Warrant Shares”). The public offering price for each Common Unit was $0.65. The Common Warrants have an exercise price of $0.65 per share, are immediately exercisable and will expire five years from the date of issuance.
     
    The net proceeds of the Offering, after deducting the placement agent’s fees and expenses and other offering expenses payable by the Company and excluding the net proceeds, if any, from the exercise of the Common Warrants, is approximately $5,582,557.50. The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes. The Offering closed on July 2, 2025.
     
    In the Purchase Agreement, the Company agreed, subject to certain exceptions, not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock or file any registration statement or prospectus, or any amendment or supplement thereto for 60 days after the closing date of the Offering. In addition, the Company has agreed not to effect or enter into an agreement to effect any issuance of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock involving a variable rate transaction (as defined in the Purchase Agreement) for six months after the closing date of the Offering, subject to certain exceptions.
     
    Each of the Placement Agency Agreement and the Purchase Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the purchasers, including for liabilities arising under the Securities Act of 1933, as amended (the “Securities Act”), other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Purchase Agreement were made only for the purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements, and may be subject to limitations agreed upon by the contracting parties.
     
    A holder will not have the right to exercise any portion of the Common Warrants if the holder (together with its affiliates) would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Common Warrants.
     
    The Company paid the Placement Agent as compensation a cash fee equal to 7.0% of the gross proceeds of the Offering plus reimbursement of certain expenses and legal fees.
     
    The Common Units, Common Warrants and Common Warrant Shares were offered by the Company pursuant to a Registration Statement on Form S-1 originally filed on June 16, 2025 with the Securities and Exchange Commission (the “SEC”) under the Securities Act (File No. 333-288085), amended on June 26, 2025 and declared effective on June 30, 2025.
     
    The foregoing description of the material terms of the Placement Agency Agreement, the Purchase Agreement and the Common Warrants is not complete and is qualified in its entirety by reference to the full text of the form of Placement Agency Agreement, the form of Purchase Agreement and the form of Common Warrant, copies of which are filed as Exhibits 10.1, 10.2 and 4.1, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.
     
    The legal opinion, including the related consent, of Womble Bond Dickinson (US) LLP relating to the legality of the securities offered, issued and sold in the Offering is filed as Exhibit 5.1 to this Current Report.
     
    Item 7.01
    Regulation FD Disclosure.
     
    On July 1, 2025, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.
     
    The information set forth in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
     
     

     
     
    Item 9.01
    Financial Statements and Exhibits.
     
    (d)
     
    Exhibits.
     
    The following Exhibits are being filed or furnished, as applicable, with this Current Report on Form 8-K.
     
    Exhibit No.
    Description
    4.1
    Form of Common Warrant
    5.1
    Opinion of Womble Bond Dickinson (US) LLP
    10.1
    Form of Placement Agency Agreement
    10.2
    Form of Purchase Agreement
    23.1
    Consent of Womble Bond Dickinson (US) LLP (contained in Exhibit 5.1)
    99.1
    Press Release dated July 1, 2025, announcing the pricing of the Offering
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL document).
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    GeoVax Labs, Inc.
       
    July 2, 2025
    By:
    /s/ Mark W. Reynolds
     
    Name:
    Mark W. Reynolds
     
    Title:
    Chief Financial Officer
     
     
     
    Get the next $GOVX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GOVX

    DatePrice TargetRatingAnalyst
    4/15/2025$18.00 → $14.00Buy
    D. Boral Capital
    4/15/2025$15.00 → $8.50Buy
    Alliance Global Partners
    11/11/2024$15.00Buy
    Alliance Global Partners
    7/16/2024$20.00Buy
    ROTH MKM
    More analyst ratings

    $GOVX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

      MIAMI, April 16, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80th Emerging Growth Conference on April 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - TodayApril 16, 2025 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to t

      4/16/25 7:00:00 AM ET
      $ASBP
      $BENF
      $BNZI
      $CIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance
    • Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream

      MIAMI, April 15, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 81th Emerging Growth Conference on April 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1April 16, 2025 9:00Virtual Lobby opens.Register for the Conference. If you already register

      4/15/25 7:00:00 AM ET
      $ASBP
      $BENF
      $BNZI
      $CIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance
    • Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now

      MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80th Emerging Growth Conference on March 26 & 27, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - TodayMarch 26, 2025 11:00Virtual Lobby opens.Register for the Conference.  If you already registered, go back to

      3/26/25 7:00:00 AM ET
      $AEMD
      $ASPI
      $ATCH
      $BNRG
      Medical/Dental Instruments
      Health Care
      Major Chemicals
      Industrials

    $GOVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital reiterated coverage on GeoVax Labs with a new price target

      D. Boral Capital reiterated coverage of GeoVax Labs with a rating of Buy and set a new price target of $14.00 from $18.00 previously

      4/15/25 7:54:48 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alliance Global Partners reiterated coverage on GeoVax Labs with a new price target

      Alliance Global Partners reiterated coverage of GeoVax Labs with a rating of Buy and set a new price target of $8.50 from $15.00 previously

      4/15/25 7:54:17 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alliance Global Partners initiated coverage on GeoVax Labs with a new price target

      Alliance Global Partners initiated coverage of GeoVax Labs with a rating of Buy and set a new price target of $15.00

      11/11/24 7:40:44 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Lemerond Nicole

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      6/6/25 9:51:40 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Chase Randal D

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      6/6/25 9:50:36 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Kollintzas Dean G

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      6/6/25 9:49:19 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Spencer John N Jr bought $9,800 worth of shares (10,000 units at $0.98), increasing direct ownership by 713% to 11,402 units (SEC Form 4)

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      4/11/25 1:23:33 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP, Business Development Sharkey John W. bought $5,940 worth of shares (6,000 units at $0.99), increasing direct ownership by 3,141% to 6,191 units (SEC Form 4)

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      4/10/25 4:01:15 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, CEO Dodd David A bought $10,800 worth of shares (10,000 units at $1.08), increasing direct ownership by 38% to 36,661 units (SEC Form 4)

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      4/1/25 4:46:16 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    SEC Filings

    See more
    • GeoVax Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - GeoVax Labs, Inc. (0000832489) (Filer)

      7/2/25 4:22:55 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B4 filed by GeoVax Labs Inc.

      424B4 - GeoVax Labs, Inc. (0000832489) (Filer)

      7/2/25 6:01:31 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by GeoVax Labs Inc.

      EFFECT - GeoVax Labs, Inc. (0000832489) (Filer)

      7/1/25 12:15:37 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by GeoVax Labs Inc.

      SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)

      11/14/24 5:10:48 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by GeoVax Labs Inc.

      SC 13G - GeoVax Labs, Inc. (0000832489) (Subject)

      2/14/24 3:38:25 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)

      2/10/21 3:16:30 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Leadership Updates

    Live Leadership Updates

    See more
    • GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board

      Strategic Appointment Enhances GeoVax's Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of Teresa Lambe, PhD, OBE, FMedSci to its Scientific Advisory Board. Professor Lambe is the Calleva Head of Vaccine Immunology at the Oxford Vaccine Group within the University of Oxford and a Principal Investigator at the Pandemic Sciences Institute (PSI). She served as one of the Principal Investigators who oversaw the Oxford/AstraZeneca vaccine program; she co-designed the vacci

      8/8/24 9:00:00 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology

      Strengthening GeoVax's Team Advancing Gedeptin® Clinical Program ATLANTA, GA, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of J. Marc Pipas, M.D., to serve as the Company's Executive Medical Director, Oncology.  Kelly McKee, M.D., MPH, GeoVax Chief Medical Officer, commented, "Dr. Pipas' addition to our team represents an important step forward in the strengthening of GeoVax's organizational and operational resources to support advancement of our principal oncology asset, Gedeptin®, through clinical development

      1/8/24 9:00:00 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax

      First Woman President and CEO of MSM and Internationally Recognized Health Equity Advocate Joins in GeoVax Special Advisory Role ATLANTA, GA, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the appointment of Valerie Montgomery Rice, MD, FACOG, Morehouse School of Medicine President and CEO, as Special Advisor to the Chairman/CEO and Board of Directors of GeoVax. Dr. Montgomery Rice brings GeoVax exceptional expertise and highly recognized experience at the highest levels of healthcare leadership, patient care, biomedical resear

      12/20/22 9:00:00 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Financials

    Live finance-specific insights

    See more
    • GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

      Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance into Phase 2 clinical trial for first recurrent head and neck cancer in the first half of 2025 GEO-MVA Mpox vaccine advancing with cGMP clinical batch anticipated during fourth quarter 2024 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced financial results for the third quarter end

      11/12/24 4:00:00 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

      GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results. Conference Call Details To access the live conference call, participants may register here. The live audio webcast of the call will be available

      11/5/24 9:00:00 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

      Awarded BARDA Project NextGen (PNG) contract to advance GeoVax's multi-antigen vaccine candidate, GEO-CM04S1, into 10,000-participant randomized, comparative Phase 2b COVID-19 vaccine study BARDA PNG award represents greater than $350 million in support of PNG GEO-CM04S1 clinical trial, including direct funding of CRO partner Allucent Multiple planned data readouts for GEO-CM04S1 throughout second half of 2024;Gedeptin® to advance into expanded Phase 2 clinical trial with activation in the first half of 2025 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, GA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developin

      8/6/24 4:00:00 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care